Author + information
- Wen Gaiyan,
- Gaiyan Wen and
- Hong Yuan
To explore relationship between CACNA1C rs1051375 polymorphisms and antihypertensive effect of amlodipine in CKD (chronic kidney disease) with hypertension patients.
34540 CKD with hypertension patients were screened in the third Xiang Ya hospital from 2009 to 2012. 200 CKD with hypertension patients were genotyped for CACNA1C rs1051375 using polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP). 104 patients were drawn randomly and sequentially received 10mg/d amlodipine for four weeks. The blood pressure at baseline, 1 week and 4 week were recorded.
31.9% (11049 in 34540 cases) CKD with hypertension patients took amlodipine. Among these 200 patients, there were 81 (40.5%) patients with AA, 78 (30.0%) with AG and 41 (20.5%) with GG in rs1051375 A > G. There was significant difference in SBP after 1 week treatment among AA, AG and GG groups(P=0.015). However, DBP after 1 week treatment showed no significant difference among these three groups (P=0.056). After 4 week treatment with amlodipine, SBP and DBP were both significantly different among AA, AG and GG groups (139.50±16.59 vs 133.33±15.07 vs 127.07±9.30 mmHg, P=0.032; 83.77±11.86 vs 79.00±12.07 vs 74.50±6.89 mmHg, P=0.044). And the DBP reduction of GG group was higher than AA and AG groups (13.85±12.64 vs 5.15±11.42 vs 5.46±11.42 mmHg, P < 0.05). However, SBP reduction showed no significant difference among three genotype groups.
Most patients carried the wild allele rs1051375A. CKD with hypertension patients with CACNA1C rs1051375GG had a better antihypertensive response to amlodipine.